Applying the median value as cut-off, NFE2L2 mRNA expression levels remained the strongest factor predicting the risk for relapse and death in the whole cohort [HRrelapse 0.3 (0.1–0.6); P = 0.001, HRdeath 0.5 (0.3–0.8); P = 0.010] (Table 3B) as well as in the ER positive tumour subgroup [HRrelapse 0.2 (0.1–0.5), P = 0.001; HRdeath 0.4 (0.2–0.8), P = 0.009] (Table 4B). This evidence concerns the gene NFE2L2 and neoplasm.